 Shares of biopharmaceutical concern Ardelyx, Inc. have fallen over 60 since the FDA initially rejected its hyperphosphatemia therapy XPHOZOA tenapanor in mid-2021. The rejection, which was very surprising given its three Phase 3 trial successes, compelled Ardelyx to lay off 60 of its workforce and significantly dilute shareholders. 